Replimune Group (REPL) Projected to Post Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.70) per share for the quarter.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Replimune Group Stock Down 5.9 %

NASDAQ REPL traded down $0.82 during mid-day trading on Monday, reaching $13.12. The stock had a trading volume of 679,785 shares, compared to its average volume of 797,438. The stock has a market cap of $897.63 million, a PE ratio of -4.30 and a beta of 1.30. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The company has a fifty day moving average price of $12.49 and a 200 day moving average price of $11.62.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company's stock, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on REPL shares. BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. HC Wainwright lifted their price objective on Replimune Group from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday, January 22nd. Finally, Jefferies Financial Group upped their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Replimune Group presently has an average rating of "Buy" and a consensus price target of $19.14.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.